Abstract
Clinical Strategies for PARP Inhibitors beyond Homologous Recombination Deficiency
recurrent ovarian cancer and today there are already three PARP inhibitors approved; olaparib, rucaparib and niraparib. PARP inhibitors selectively target cancers with mutation of BRCA1 or BRCA2 alleles owing to their homologous recombination deficiency (HRD).
Author(s): Thomas Helleday
Warning: Undefined variable $art_rows in /efsdata/imedpub-com/abstract/abstract-page.php on line 110
Warning: Attempt to read property "select_abs_row" on null in /efsdata/imedpub-com/abstract/abstract-page.php on line 110
Abstract | Full-Text | PDF
Share This Article
Awards Nomination
17+ Million Readerbase
Google Scholar citation report
Citations : 134
Journal of Medical Oncology received 134 citations as per Google Scholar report
Open Access Journals
- Aquaculture & Veterinary Science
- Chemistry & Chemical Sciences
- Clinical Sciences
- Engineering
- General Science
- Genetics & Molecular Biology
- Health Care & Nursing
- Immunology & Microbiology
- Materials Science
- Mathematics & Physics
- Medical Sciences
- Neurology & Psychiatry
- Oncology & Cancer Science
- Pharmaceutical Sciences